.jpg)
FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time
The biopharmaceutical company Cellectar Biosciences recently announced that the FDA granted its lead phospholipid drug conjugate, CLR 131, Orphan Drug Designation(ODD) for treatment of lymphoplasmacytic lymphoma. ODD is granted by…
Continue Reading
FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time
